A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Inclusion Criteria:

• Between 50 and 90 years of age

• Participants with diagnosis of macular neovascularization secondary to age-relatedmacular degeneration (nAMD)

• Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for doseescalation (Part I) between 20/32 and 20/400 and for expansion (Part II) between 20/25 and 20/200

• Currently receiving anti-VEGF treatment in the study eye

• Demonstrated a response to aflibercept in the pre-treatment period

Exclusion Criteria:

• Any condition in the study eye that may prevent visual acuity improvement orinterfere with ocular safety or efficacy assessments

• History of active ocular infection in the study eye in 6 months prior to screening

• Active uncontrolled glaucoma in the study eye

• History of uveitis in either eye

• Use of ocular corticosteroids in the 3 months prior to screening

• Previous gene therapy

• Any significant poorly controlled illness that would preclude study compliance andfollow up

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.